{"Title": "A roadmap for cost-of-goods planning to guide economic production of cell therapy products", "Year": 2017, "Source": "Cytotherapy", "Volume": "19", "Issue": 12, "Art.No": null, "PageStart": 1383, "PageEnd": 1391, "CitedBy": 25, "DOI": "10.1016/j.jcyt.2017.06.009", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85029537058&origin=inward", "Abstract": "\u00a9 2017 International Society for Cellular TherapyCell therapy products are frequently developed and produced without incorporating cost considerations into process development, contributing to prohibitively costly products. Herein we contextualize individual process development decisions within a broad framework for cost-efficient therapeutic manufacturing. This roadmap guides the analysis of cost of goods (COG) arising from tissue procurement, material acquisition, facility operation, production, and storage. We present the specific COG considerations related to each of these elements as identified through a 2013 International Society for Cellular Therapy COG survey, highlighting the differences between autologous and allogeneic products. Planning and accounting for COG at each step in the production process could reduce costs, allowing for more affordable market pricing to improve the long-term viability of the cell therapy product and facilitate broader patient access to novel and transformative cell therapies.", "AuthorKeywords": ["allogeneic cell products", "autologous cell products", "cell therapy", "COG", "cost of goods", "facility costs", "material costs", "production costs", "storage", "tissue procurement"], "IndexKeywords": ["Cell- and Tissue-Based Therapy", "Commerce", "Costs and Cost Analysis", "Humans"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85029537058", "SubjectAreas": [["Immunology and Allergy", "MEDI", "2723"], ["Immunology", "IMMU", "2403"], ["Oncology", "MEDI", "2730"], ["Genetics (clinical)", "MEDI", "2716"], ["Cell Biology", "BIOC", "1307"], ["Cancer Research", "BIOC", "1306"], ["Transplantation", "MEDI", "2747"]], "AuthorData": {"56711905800": {"Name": "Lipsitz Y.Y.", "AuthorID": "56711905800", "AffiliationID": "60089742, 60016849", "AffiliationName": "Institute for Biomaterials and Biomedical Engineering, University of Toronto"}, "57190295853": {"Name": "Milligan W.D.", "AuthorID": "57190295853", "AffiliationID": "118205141", "AffiliationName": "Steminent Biotherapeutics"}, "55888884800": {"Name": "Fitzpatrick I.", "AuthorID": "55888884800", "AffiliationID": "119267523", "AffiliationName": "Scinogy Pty Ltd"}, "57195685094": {"Name": "Stalmeijer E.", "AuthorID": "57195685094", "AffiliationID": "119267632", "AffiliationName": "eXmoor Pharma Concepts"}, "7005343335": {"Name": "Farid S.S.", "AuthorID": "7005343335", "AffiliationID": "60022148", "AffiliationName": "University College London"}, "37001421100": {"Name": "Tan K.Y.", "AuthorID": "37001421100", "AffiliationID": "60113363", "AffiliationName": "Bioprocessing Technology Institute, A*STAR"}, "35204639100": {"Name": "Chen A.", "AuthorID": "35204639100", "AffiliationID": "60113363", "AffiliationName": "Bioprocessing Technology Institute, A*STAR"}, "7410359398": {"Name": "Smith D.", "AuthorID": "7410359398", "AffiliationID": "116142659", "AffiliationName": "PCT, a Caladrius Company"}, "57212688360": {"Name": "Perry R.", "AuthorID": "57212688360", "AffiliationID": "60175972", "AffiliationName": "Atara Biotherapeutics"}, "55829144200": {"Name": "Carmen J.", "AuthorID": "55829144200", "AffiliationID": "60116226", "AffiliationName": "MaxCyte"}, "57195671483": {"Name": "Mooney C.", "AuthorID": "57195671483", "AffiliationID": "60021431", "AffiliationName": "Oklahoma Blood Institute"}, "57195681849": {"Name": "Fink J.", "AuthorID": "57195681849", "AffiliationID": "60080539", "AffiliationName": "Brooks Automation"}}}